Synthesis of eosinophil infiltration inhibitors with antihistaminic activity.
A series of [1, 2, 4]triazolo[1, 5-b]pyridazines (5) and imidazo[1, 2-b]pyridazines (6) having cyclic amines was synthesized and evaluated for antihistaminic activity and inhibitory effect on eosinophil infiltration. When a piperidine or a piperazine containing a benzhydryl group and a suitable spacer was incorporated at the 6-position, the fused pyridazines were found to exhibit both antihistaminic activity and an inhibitory effect on eosinophil chemotaxis. Above all, 6a showed potent antihistaminic activity, but little blockade of central H(1) receptors in contrast with its complete blockade of peripheral H(1) receptors as determined by an ex vivo binding assay. Furthermore, 6a inhibited eosinophil infiltration of the skin caused by a topical antigen challenge in sensitized guinea pigs, while an antihistamine terfenadine was not effective. After the pharmacokinetic study, 6a was found to be rapidly hydrolyzed to 6o, which was also orally active. Compound 6o, 2-[6-[[3-[4-(diphenylmethoxy)piperidino]propyl]amino]imidazo[1, 2-b]pyridazin-2-yl]-2-methylpropionic acid dihydrate (TAK-427), having both antihistaminic and antiinflammatory activity, is currently undergoing clinical trials as a therapeutic agent for atopic dermatitis and allergic rhinitis.
Gyoten
Michiyo
M
Pharmaceutical Research Division, Takeda Chemical Industries, Ltd, Osaka, Japan. gyoten_michiyo@teakeda.co.jp
Nagaya
Hideaki
H
Fukuda
Shigeru
S
Ashida
Yasuko
Y
Kawano
Yasuhiko
Y
D000818:Animals; D004804:Eosinophils / Q000166:cytology* / Q000187:drug effects*; D006168:Guinea Pigs; D006634:Histamine H1 Antagonists / Q000138:chemical synthesis* / Q000494:pharmacology*; D008297:Male; D014132:Trachea / Q000166:cytology / Q000187:drug effects / Q000378:metabolism
D006634:Histamine H1 Antagonists